Skip to main content
Top
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

Overexpression of NKX6.1 is closely associated with progressive features and predicts unfavorable prognosis in human primary hepatocellular carcinoma

Authors: Lin-Lin Huang, Yi Zhang, Jia-Xing Zhang, Long-Jun He, Ying-Rong Lai, Yi-Ji Liao, Xiao-Peng Tian, Hai-Xia Deng, Ying-Jie Liang, Hsiang-Fu Kung, Dan Xie, Sen-Lin Zhu

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

The homeobox gene NKX6.1 was recently identified in cervical tumors. This study was designed to explore the clinical and prognostic significance of NKX6.1 further in patients with primary hepatocellular carcinoma (HCC). The expression levels of NKX6.1 were examined using real-time PCR, Western blotting, and immunohistochemistry in HCC cell lines and HCC tissues. The invasion capability of cell lines following silencing or overexpression of NKX6.1 was investigated by Transwell assay. Cells proliferation was tested by MTT assays. Epithelial–mesenchymal transition (EMT) marker expression levels were detected in relation to NKX6.1 expression. Correlation between NKX6.1 immunohistochemical staining, clinicopathologic parameters, and follow-up data of HCC patients was analyzed statistically. NKX6.1 expression was higher in HCC tissues compared to the adjacent noncancerous tissue. NKX6.1 overexpression was significantly correlated with tumor size, tumor differentiation, clinical stage, metastasis, and relapse. Kaplan–Meier analysis revealed that NKX6.1 overexpression was related to unfavorable 5-year disease-free survival and overall survival. Importantly, multivariate analysis indicated that NKX6.1 overexpression was an independent unfavorable marker for overall survival. Moreover, a significant relationship was observed between NKX6.1 and EMT marker expression levels, and NKX6.1 knockdown inhibited cell invasion, and overexpression of NKX6.1 promotes cell proliferation in vitro. NKX6.1 is upregulated in HCC and is a reliable prognostic marker for patients with HCC.
Literature
1.
go back to reference Tsuzura H, Genda T, Sato S, Murata A, Kanemitsu Y, et al. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis. Int J Mol Sci. 2014;15:6556–68.CrossRefPubMedPubMedCentral Tsuzura H, Genda T, Sato S, Murata A, Kanemitsu Y, et al. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis. Int J Mol Sci. 2014;15:6556–68.CrossRefPubMedPubMedCentral
2.
go back to reference Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014: Article ID:741465. Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014: Article ID:741465.
3.
go back to reference Ji Z, Wang B. Identifying potential clinical syndromes of hepatocellular carcinoma using PSO-based hierarchical feature selection algorithm. Biomed Res Int. 2014: Article ID:127572. Ji Z, Wang B. Identifying potential clinical syndromes of hepatocellular carcinoma using PSO-based hierarchical feature selection algorithm. Biomed Res Int. 2014: Article ID:127572.
4.
go back to reference Kikuchi L, Oliveira CP, Carrilho FJ. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Biomed Res Int. 2014:Article ID:106247. Kikuchi L, Oliveira CP, Carrilho FJ. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Biomed Res Int. 2014:Article ID:106247.
5.
go back to reference El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–34.CrossRefPubMed El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–34.CrossRefPubMed
6.
7.
go back to reference Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, et al. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut. 2011;60:967–76.CrossRefPubMed Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, et al. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut. 2011;60:967–76.CrossRefPubMed
8.
go back to reference Hsu YC, Fu HH, Jeng YM, Lee PH, Yang SD. Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J Clin Oncol. 2006;24:3780–8.CrossRefPubMed Hsu YC, Fu HH, Jeng YM, Lee PH, Yang SD. Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J Clin Oncol. 2006;24:3780–8.CrossRefPubMed
9.
go back to reference Ma P, Xia Y, Ma L, Zhao S, Mao B. Xenopus Nkx6.1 and Nkx6.2 are required for mid-hindbrain boundary development. Dev Genes Evol. 2013;223:253–9.CrossRefPubMed Ma P, Xia Y, Ma L, Zhao S, Mao B. Xenopus Nkx6.1 and Nkx6.2 are required for mid-hindbrain boundary development. Dev Genes Evol. 2013;223:253–9.CrossRefPubMed
10.
go back to reference Lai HC, Lin YW, Huang TH, Yan P, Huang RL, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008;123:161–7.CrossRefPubMed Lai HC, Lin YW, Huang TH, Yan P, Huang RL, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008;123:161–7.CrossRefPubMed
12.
go back to reference Rahmatpanah FB, Carstens S, Guo J, Sjahputera O, Taylor KH, et al. Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior. Leukemia. 2006;20:1855–62.CrossRefPubMed Rahmatpanah FB, Carstens S, Guo J, Sjahputera O, Taylor KH, et al. Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior. Leukemia. 2006;20:1855–62.CrossRefPubMed
13.
go back to reference Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin N Am. 2003;83:803–19.CrossRefPubMed Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin N Am. 2003;83:803–19.CrossRefPubMed
14.
go back to reference Zhang Y, Zhang JX, Huang LL, He LJ, Liao YJ, et al. Low expression of BARX2 in human primary hepatocellular carcinoma correlates with metastasis and predicts poor prognosis. Hepatol Res. 2014. doi:10.1111/hepr.12340. Zhang Y, Zhang JX, Huang LL, He LJ, Liao YJ, et al. Low expression of BARX2 in human primary hepatocellular carcinoma correlates with metastasis and predicts poor prognosis. Hepatol Res. 2014. doi:10.​1111/​hepr.​12340.
15.
go back to reference Lin SC, Chen WY, Lin KY, Chen SH, Chang CC, et al. Clinicopathological correlation and prognostic significance of protein kinase cα overexpression in human gastric carcinoma. PLoS ONE. 2013;8:e56675.CrossRefPubMedPubMedCentral Lin SC, Chen WY, Lin KY, Chen SH, Chang CC, et al. Clinicopathological correlation and prognostic significance of protein kinase cα overexpression in human gastric carcinoma. PLoS ONE. 2013;8:e56675.CrossRefPubMedPubMedCentral
16.
go back to reference Liu L, Dai Y, Chen J, Zeng T, Li Y, et al. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition via Akt/GSK-3β/snail signaling. Hepatology. 2014;59:531–43.CrossRefPubMed Liu L, Dai Y, Chen J, Zeng T, Li Y, et al. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition via Akt/GSK-3β/snail signaling. Hepatology. 2014;59:531–43.CrossRefPubMed
17.
go back to reference Bertran E, Crosas-Molist E, Sancho P, Caja L, Lopez-Luque J, et al. Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology. 2013;58:2032–44.CrossRefPubMed Bertran E, Crosas-Molist E, Sancho P, Caja L, Lopez-Luque J, et al. Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology. 2013;58:2032–44.CrossRefPubMed
18.
go back to reference Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191–211.CrossRefPubMed Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191–211.CrossRefPubMed
19.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
20.
go back to reference Ferlay JSH, Bray F, Forman D, Mathers CD, Parkin D. GLOBOCAN 2008, Cancer incidence and mortality worldwide. IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer. [Cited 17 Aug 2010.] Available from: http://globocan.iarc.fr 2010 Last accessed 8/17/2010. Ferlay JSH, Bray F, Forman D, Mathers CD, Parkin D. GLOBOCAN 2008, Cancer incidence and mortality worldwide. IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer. [Cited 17 Aug 2010.] Available from: http://​globocan.​iarc.​fr 2010 Last accessed 8/17/2010.
21.
go back to reference Zhang CZ, Liu L, Cai M, Pan Y, Fu J, et al. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS ONE. 2012;7:e51703.CrossRefPubMedPubMedCentral Zhang CZ, Liu L, Cai M, Pan Y, Fu J, et al. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS ONE. 2012;7:e51703.CrossRefPubMedPubMedCentral
22.
go back to reference Du D, Liu Y, Qian H, Zhang B, Tang X, et al. The effects of the CCR6/CCL20 biological axis on the invasion and metastasis of hepatocellular carcinoma. Int J Mol Sci. 2014;15:6441–52.CrossRefPubMedPubMedCentral Du D, Liu Y, Qian H, Zhang B, Tang X, et al. The effects of the CCR6/CCL20 biological axis on the invasion and metastasis of hepatocellular carcinoma. Int J Mol Sci. 2014;15:6441–52.CrossRefPubMedPubMedCentral
23.
go back to reference Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559–80.CrossRefPubMedPubMedCentral Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559–80.CrossRefPubMedPubMedCentral
24.
go back to reference Han MS, Moon KS, Lee KH, Cho SB, Lim SH, et al. Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor. BMC Cancer. 2013;13:567.CrossRefPubMedPubMedCentral Han MS, Moon KS, Lee KH, Cho SB, Lim SH, et al. Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor. BMC Cancer. 2013;13:567.CrossRefPubMedPubMedCentral
25.
go back to reference Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012;61:278–89.CrossRefPubMed Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012;61:278–89.CrossRefPubMed
26.
go back to reference Cole L, Anderson M, Antin PB, Limesand SW. One process for pancreatic beta-cell coalescence into islets involves an epithelial-mesenchymal transition. J Endocrinol. 2009;203:19–31.CrossRefPubMedPubMedCentral Cole L, Anderson M, Antin PB, Limesand SW. One process for pancreatic beta-cell coalescence into islets involves an epithelial-mesenchymal transition. J Endocrinol. 2009;203:19–31.CrossRefPubMedPubMedCentral
Metadata
Title
Overexpression of NKX6.1 is closely associated with progressive features and predicts unfavorable prognosis in human primary hepatocellular carcinoma
Authors
Lin-Lin Huang
Yi Zhang
Jia-Xing Zhang
Long-Jun He
Ying-Rong Lai
Yi-Ji Liao
Xiao-Peng Tian
Hai-Xia Deng
Ying-Jie Liang
Hsiang-Fu Kung
Dan Xie
Sen-Lin Zhu
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3080-4

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine